Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment

Samankaltaisia teoksia

• Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment
  Tekijä: Yang CJ, et al.
  Julkaistu: (2016-03-01)
• The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
  Tekijä: Yang, Chih-Jen, et al.
  Julkaistu: (2017)
• Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
  Tekijä: Yang, Chih-Jen, et al.
  Julkaistu: (2016)
• Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations
  Tekijä: WU, WEN-SHUO, et al.
  Julkaistu: (2012)
• Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
  Tekijä: Yuan, Ying, et al.
  Julkaistu: (2012)